Orexo AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
429,355.00
570,316.00
646,200.00
705,900.00
643,700.00
783,100
Cost of Goods Sold (COGS) incl. D&A
33,919.00
113,415.00
225,100.00
171,000.00
185,200.00
190,400
Gross Income
395,436.00
456,901.00
421,100.00
534,900.00
458,500.00
592,700
SG&A Expense
485,040.00
498,443.00
599,000.00
513,100.00
400,000.00
423,500
EBIT
103,272.00
41,542.00
-
21,800.00
58,500.00
169,200
Unusual Expense
43,923.00
4,700.00
-
-
-
82,800
Non Operating Income/Expense
7,506.00
21,235.00
65,000.00
30,800.00
7,000.00
19,200
Interest Expense
13,712.00
27,804.00
23,000.00
23,800.00
21,900.00
16,500
Pretax Income
153,401.00
52,554.00
203,600.00
35,600.00
29,700.00
92,200
Income Tax
1,535.00
4,030.00
6,400.00
6,600.00
6,500.00
45,700
Consolidated Net Income
154,936.00
56,584.00
210,000.00
29,000.00
23,200.00
137,900
Net Income
154,936.00
56,584.00
210,000.00
29,000.00
23,200.00
137,900
Net Income After Extraordinaries
154,936.00
56,584.00
210,000.00
29,000.00
23,200.00
137,900
Net Income Available to Common
154,936.00
56,584.00
210,000.00
29,000.00
23,200.00
137,900
EPS (Basic)
5.16
1.73
6.09
0.84
0.67
3.99
Basic Shares Outstanding
30,018.00
32,657.20
34,478.60
34,477.40
34,561.10
34,560.50
EPS (Diluted)
4.77
1.61
6.09
0.84
0.67
3.93
Diluted Shares Outstanding
32,449.00
35,241.20
34,478.60
34,574.40
34,671.70
35,096
EBITDA
97,076.00
29,015.00
34,800.00
43,200.00
79,300.00
190,000
Other Operating Expense
13,668.00
-
62,300.00
-
-
-
Non-Operating Interest Income
-
257.00
-
6,800.00
100.00
3,000

About Orexo AB

View Profile
Address
Rapsgatan 7e
Uppsala UP 751 05
Sweden
Employees -
Website http://www.orexo.com
Updated 07/08/2019
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. Its pipeline comprises of Zubsolv, Abstral, Edluar, Zubsolv, OX51, OX-MP1, and OX382.